ArticleNature biotechnology2022
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.
Abstract read
In one paragraph
Article in Nature biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
176 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.Nature communications · 2025Pooled it
- Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2024Pooled it
- Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer.Nature cancer · 2026Trial
- Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.Nature communications · 2024Trial
- Generalizable AI predicts immunotherapy outcomes across cancers and treatments.Nature medicine · 2026Article
- Artificial Intelligence-Enabled Exosomes in Precision Oncology: A Framework for Clinical Utility and Biomedical Applications.Current issues in molecular biology · 2026Review
- A Radioresistant-Tumor-Targeted Nanoparticle for X-Ray-Controlled Nitric Oxide Release to Potentiate Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Article
- Biomaterials for biomarker imaging and detection.Journal of advanced research · 2026Review
- Proteome profiles of esophageal squamous cell carcinoma tie mitochondrial complex I to immunotherapy.EMBO molecular medicine · 2026Article
- The impact of PD-1 mutations on pembrolizumab binding: insights from molecular dynamics and MM-GBSA analysis.Scientific reports · 2026Article
- Exon inclusion signatures enable accurate estimation of splicing factor activity.Nature communications · 2026Article
- Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors.Scientific reports · 2026Article
- Immune Predictors of Radiotherapy Outcomes in Cervical Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Enhanced CT-based deep learning radiomics and biological correlations for predicting immunotherapy efficacy in advanced non-small cell lung cancer.Translational cancer research · 2026Article
- Real-World Genomic Landscape of Korean Gastric Cancer: Integrating Biomarker Associations and Clinical Outcomes in Metastatic Gastric Cancer.JCO precision oncology · 2026Article
- [Construction of a prognosis forecasting model for immuno-therapy response in cancer patients by integrating routine clinical parameters and tumor mutational burden].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Towards Precision Oncology: How Advances in Cancer Genomics, Immunobiology and Artificial Intelligence Will Change Molecular Diagnostics.Biomedicines · 2026Review
- PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.Military Medical Research · 2026Article
116 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Diego Chowell *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Seong-Keun Yoo *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-8749-7050
Cristina Valero *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3397-2888
Alessandro Pastore *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3621-4807
Chirag KrishnaComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Douglas HoenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hongyu ShiComputational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel W KellyInformation Systems, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Neal PatelHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4352-4723
Vladimir MakarovHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Xiaoxiao MaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lynda VuongHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Erich Y SabioHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kate WeissHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Fengshen KuoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-1797-2896
Tobias L LenzResearch Unit for Evolutionary Immunogenomics, Department of Biology, Universität Hamburg, Hamburg, Germany.ORCID http://orcid.org/0000-0002-7203-0044
Robert M SamsteinPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nadeem RiazHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9873-5862
Prasad S AdusumilliDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-1699-2046
Vinod P BalachandranHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2956-223X
George PlitasDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
A Ari HakimiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3907-6171
Alexander N ShoushtariDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael A PostowDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert J MotzerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ahmet ZehirDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5406-4104
Michael F BergerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3882-5000
Mithat GönenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luc G T MorrisHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. morrisl@mskcc.org.ORCID http://orcid.org/0000-0002-4417-2280
Nils WeinholdImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. weinholn@mskcc.org.ORCID http://orcid.org/0000-0003-3290-6192
Timothy A ChanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant2@ccf.org.ORCID http://orcid.org/0000-0002-9265-0283
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCER35CA232097 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY · 2018 to 2024
$7.0MElucidating genetics of response to immune checkpoint blockade in lung cancerR01CA205426 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHAN, TIMOTHY AN-THY, RIZVI, NAIYER A · 2017 to 2021
$3.2MIdentifying and targeting neoantigens in aggressive salivary carcinomasR01DE027738 · NIDCR · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY, HO, ALAN L. · 2018 to 2022
$2.8MDissecting the influence of DNA damage response and homologous recombination deficiencies on tumor immunogenicityDP5OD028171 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SAMSTEIN, ROBERT M · 2019 to 2023
$2.2MFunctionalizing recurrent FAT1 mutations and deletions in oral cancerK08DE024774 · NIDCR · SLOAN-KETTERING INST CAN RESEARCH · PI MORRIS, LUC GORDON TRANG · 2014 to 2018
$682kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA205426NCI NIH HHS R35 CA232097NIDCR NIH HHS K08 DE024774NIDCR NIH HHS R01 DE027738NIH HHS DP5 OD028171
Abstract
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB) treatment, but current decision-making procedures have limited accuracy. In this study, we developed a machine learning model to predict ICB response by integrating genomic, molecular, demographic and clinical data from a comprehensively curated cohort (MSK-IMPACT) with 1,479 patients treated with ICB across 16 different cancer types. In a retrospective analysis, the model achieved high sensitivity and specificity in predicting clinical response to immunotherapy and predicted both overall survival and progression-free survival in the test data across different cancer types. Our model significantly outperformed predictions based on tumor mutational burden, which was recently approved by the U.S. Food and Drug Administration for this purpose
Indexed as
Immune Checkpoint InhibitorsNeoplasmsBiomarkers, TumorHumansImmunotherapyMutationRetrospective StudiesBiomarkers, TumorImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.